The first locally and Arab .. Opening a laboratory for the manufacture of chemical drugs against cancerous tumors

Damascus-Sana

A laboratory for the manufacture of anti-cancer drugs, which is affiliated to the Central Pharmaceutical Industries Company (MINPARMA), was inaugurated today in Adra Industrial City in Damascus countryside.

The production capacity of the plant, which seeks to ensure the availability of medicine in the market at economical prices to 6000 vials and ampoules per hour from the aseptic fluid line and 12000 tablets per hour from the line of tablets and uses the latest production techniques and analysis of world-class.

The Minister of Health Dr. Nizar Yazji said during the opening of the laboratory that it constitutes a qualitative leap in the pharmaceutical industry in Syria, in addition to being the first laboratory in Syria in this field, pointing out that the number of licensed pharmaceutical laboratories in Syria is 96 factories that provide more than 90 percent of the needs of the local market.

The Minister of Health pointed out that the ministry's plan to work on the manufacture of generic drugs, especially for the treatment of cancer and vaccines to ensure the need of the local market, pointing out that he monitored the import of chronic drugs and anti-tumors and vaccines last year 117 billion Syrian pounds, where the ministry to import from friendly countries after the exit of agents of a number of pharmaceutical companies Foreigners from Syria as a result of the terrorist war and unilateral coercive economic measures.

Dr. Yazji confirmed that the ministry provides free medication for chronic diseases through 1864 health centers and about 150 hospitals in various governorates.

For his part, Governor of Rural Damascus Eng. Alaa Mounir Ibrahim said that the concerned authorities provide all facilities for the establishment of industrial facilities in various fields, noting that the number of facilities and factories in the industrial city of Adra reached 1200 factories and is expected to reach next year to 2400 factories, including 20 factories for pharmaceutical manufacturing.

Adnan Jaafo, CEO of the company, explained in a statement to SANA that the factory, which opened with national expertise, "is the first of its kind in Syria and the Arab region in terms of advanced production lines and modern technologies."

The plant covers 70 percent of the total chemotherapeutic drugs and its production, he said.

In 2020, the plant will start producing 8 varieties of aseptic liquid line and 8 varieties of compressed grain line as the first stage to reach the target of 20 varieties in each line by the end of next year, according to the CEO, who confirmed that these varieties will achieve the quality equation with more price.

It is noteworthy that Syria imports all drugs oncology from abroad with other quality drugs and vaccines, while the national production covers about 90 percent of the rest of the varieties of the local market need.

Ines Svan